Should I buy or sell Homology Medicines stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FIXX shares. View FIXX analyst ratings or view top-rated stocks .

What is Homology Medicines' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price objectives for Homology Medicines' shares. Their FIXX share price targets range from $0.75 to $0.75. On average, they expect the company's share price to reach $0.75 in the next twelve months. View analysts price targets for FIXX or view top-rated stocks among Wall Street analysts .

When is Homology Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FIXX earnings forecast .

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The company earned $1.68 million during the quarter, compared to analyst estimates of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%.

When did Homology Medicines' stock split?

Homology Medicines's stock split on Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly issued shares were issued to shareholders after the market closes on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT) , Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Gossamer Bio (GOSS) , Spero Therapeutics (SPRO) , Alector (ALEC) , Dynavax Technologies (DVAX) , Advanced Micro Devices (AMD) , Inovio Pharmaceuticals (INO) .

When did Homology Medicines IPO?

Homology Medicines (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Homology Medicines?

Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FIXX

Homology Medicines (FIXX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free FIXX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $0.30
▼
$0.93
52-Week Range: N/A

Volume: 401,400 shs
Average Volume: 390,307 shs
Market Capitalization: $54.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $0.75

Get Homology Medicines alerts:

Homology Medicines MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: ∞ Upside
$0.75 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.33
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.75) to ($0.70) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

698th out of 919 stocks

Pharmaceutical Preparations Industry

303rd out of 405 stocks

3.3

Analyst's Opinion

Consensus Rating
Homology Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Homology Medicines has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for FIXX.

0.0

Dividend Strength

Dividend Yield
Homology Medicines does not currently pay a dividend.
Dividend Growth
Homology Medicines does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Homology Medicines has received a 78.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Homology Medicines is -0.33.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for FIXX on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Homology Medicines insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.10% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.32% of the stock of Homology Medicines is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Homology Medicines are expected to grow in the coming year, from ($0.75) to ($0.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Homology Medicines is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Homology Medicines is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Homology Medicines Stock (NASDAQ:FIXX)

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

FIXX Stock News Headlines

March 24, 2024 | finanznachrichten.de

Homology Medicines, Inc.: Homology Medicines Declares Distribution to Common Stockholders

March 23, 2024 | seekingalpha.com

FIXX Homology Medicines, Inc.

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 18, 2024 | finance.yahoo.com

Homology Medicines Declares Distribution to Common Stockholders

February 27, 2024 | businesswire.com

HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

February 2, 2024 | investing.com

Homology Medicines Inc (FIXX)

January 4, 2024 | finanznachrichten.de

Homology Medicines, Inc.: Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

January 4, 2024 | msn.com

Homology Medicines gets non-compliance notice from Nasdaq

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 3, 2024 | finance.yahoo.com

Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

December 27, 2023 | benzinga.com

Homology Medicines Stock (NASDAQ:FIXX) Insider Trades

December 27, 2023 | benzinga.com

Homology Medicines Stock (NASDAQ:FIXX), Short Interest Report

November 21, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, SRC, PATI, FIXX

November 17, 2023 | businesswire.com

HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

November 17, 2023 | businesswire.com

HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

November 17, 2023 | bizjournals.com

Big Pharma-backed startup to go public by merging with gutted Homology

November 16, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Homology Medicines (FIXX), Align Tech (ALGN) and Calidi Biotherapeutics (CLDI)

November 16, 2023 | msn.com

Homology Medicines slumps after merger deal with Q32 Bio

November 16, 2023 | msn.com

Why Is Rare Disease Focused Homology Medicines Stock Trading Lower Today?

November 16, 2023 | tmcnet.com

FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders

November 16, 2023 | marketwatch.com

Homology Medicines Shares Drop 38% After Buyout Offer From Q32 Bio

November 16, 2023 | markets.businessinsider.com

Homology Medicines To Merge With Q32 Bio; Homology Medicines Down In Pre-market

November 16, 2023 | finance.yahoo.com

Q32 Bio and Homology Medicines Announce Merger Agreement

November 15, 2023 | finanznachrichten.de

Homology Medicines, Inc.: Homology Medicines Reports Third Quarter 2023 Financial Results

November 14, 2023 | msn.com

Homology Medicines GAAP EPS of -$0.57 misses by $0.15

November 14, 2023 | finance.yahoo.com

Homology Medicines Reports Third Quarter 2023 Financial Results

October 28, 2023 | finance.yahoo.com

Can Homology Medicines (NASDAQ:FIXX) Afford To Invest In Growth?

See More Headlines

Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:FIXX
CUSIP: N/A
CIK: 1661998
Web: www.homologymedicines.com
Phone: (781) 301-7277
Fax: N/A
Employees: 7
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $0.75
High Stock Price Target: $0.75
Low Stock Price Target: $0.75
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,960,000.00
Net Margins: -4,779.31%
Pretax Margin: -7,532.87%
Return on Equity: -102.52%
Return on Assets: -74.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.25
Quick Ratio: 7.25

Sales & Book Value

Annual Sales: $1.16 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.26 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 58,130,000
Free Float: 48,774,000
Market Cap: $54.33 million
Optionable: Optionable
Beta: -0.10

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Paul Alloway J.D. (Age 52)
Ph.D., President & COO
Comp: $661.45k
Dr. Saswati Chatterjee Ph.D.
Co-Founder & Member of Scientific Advisory Board
Mr. Charles Michaud Jr.
CPA, VP of Finance, Corporate Controller & Treasurer
Ms. Theresa McNeely (Age 60)
Chief Communications Officer & Patient Advocate

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FIXX Stock Analysis - Frequently Asked Questions

Should I buy or sell Homology Medicines stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FIXX shares.
View FIXX analyst ratings or view top-rated stocks.
What is Homology Medicines' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price objectives for Homology Medicines' shares. Their FIXX share price targets range from $0.75 to $0.75. On average, they expect the company's share price to reach $0.75 in the next twelve months.
View analysts price targets for FIXX or view top-rated stocks among Wall Street analysts.
When is Homology Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FIXX earnings forecast.
How were Homology Medicines' earnings last quarter?: Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The company earned $1.68 million during the quarter, compared to analyst estimates of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%.

When did Homology Medicines' stock split?: Homology Medicines's stock split on Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly issued shares were issued to shareholders after the market closes on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.
What other stocks do shareholders of Homology Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO).
When did Homology Medicines IPO?: Homology Medicines (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Homology Medicines?: Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FIXX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Homology Medicines (FIXX) Stock Price, News & Analysis

Homology Medicines MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Homology Medicines Stock (NASDAQ:FIXX)

FIXX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

FIXX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™